Back

From evidence to practice: Mavacamten in obstructive Hypertrophic Cardiomyopathy - data from the multicenter TORCH-Plus-DZHK21 registry

31 August 2026 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Cardiac myosin inhibitors: real-world data Hypertrophic Cardiomyopathy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Jan Koelemen

University Hospital Heidelberg, Heidelberg (Germany)

5 More presentations in this session

Presentation thumbnail
Real-world data on the use of mavacamten in obstructive hypertrophic cardiomyopathy: one-year data from the multicentre MARVEL.HU study involving 133 patients
Doctor R. Sepp (Szeged, HU)
Abstract
Presentation thumbnail
Surgical myectomy after mavacamten discontinuation in obstructive hypertrophic cardiomyopathy: a real-world case series
Doctor C. Nie (Beijing, CN)
Abstract
Presentation thumbnail
Predictors of functional status and quality-of-life improvement with mavacamten in obstructive hypertrophic cardiomyopathy: one-year results from a real-world nationwide cohort
Doctor G. Bonacchi (Florence, IT)
Abstract
Presentation thumbnail
Real-world experience and structural remodeling with cardiac myosin inhibitors in hypertrophic obstructive cardiomyopathy: Insights from a Heart Failure Network Registry
Doctor D. Jurczyk (Luebeck, DE)
Abstract
Presentation thumbnail
Correlation of electrocardiographic reverse remodelling with treatment response to mavacamten in hypertrophic obstructive cardiomyopathy
Mr M. Menhem (Erlangen, DE)
Abstract

Access the full session

Session thumbnail
Cardiac myosin inhibitors: real-world data

The Event

Event poster

ESC Congress 2026

31 August 2026 13:15 CET
You may be interested in
thumbnail
Congress Presentation
The cardiac myosin inhibitor mavacamten reduces even extreme left ventricular outflow gradient in obstructive hypertrophic cardiomyopathy already after one week of treatment
12 December 2024
thumbnail
Congress Presentation
Population estimates of obstructive and non-obstructive hypertrophic cardiomyopathy in the UK and Germany
27 August 2022
thumbnail
Congress Presentation
Real-world health status changes with mavacamten in symptomatic obstructive hypertrophic cardiomyopathy (oHCM) - Early findings from COMPASS-HCM
29 August 2025
thumbnail
Congress Presentation
Cohort of patients with hypertrophic cardiomyopathy and alpha tropomyosin 1 variants followed up at a national reference center
27 August 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources